CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rising geriatric population
3.4.1.2. Increasing prevalence of stroke and hypertension
3.4.1.3. Lifestyle modifications which increase the risk of aSAH

3.4.2. Restraints

3.4.2.1. Side effects of the drugs

3.4.3. Opportunities

3.4.3.1. Need for growing awareness about the treatment of aSAH

3.4.4. Impact analyses

CHAPTER 4: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Patients treated, by drug class
4.1.2. Market size and forecast

4.2. Opioid analgesics

4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast by region
4.2.3. Market analysis by country

4.3. Calcium channel blockers

4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast by region
4.3.3. Market analysis by country

4.4. Anticonvulsants

4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast by region
4.4.3. Market analysis by country

4.5. Stool softeners

4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast by region
4.5.3. Market analysis by country

4.6. Osmotic agents/diuretics

4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast by region
4.6.3. Market analysis by country

4.7. Other drugs

4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast by region
4.7.3. Market analysis by country

CHAPTER 5: ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. North America

5.2.1. Key market trends, growth factors & opportunities
5.2.2. Market size and forecast by country

5.2.2.1. U.S.

5.2.2.1.1. U.S. aneurysmal subarachnoid hemorrhage market, by drug class

5.2.2.2. Canada

5.2.2.2.1. Canada aneurysmal subarachnoid hemorrhage market, by drug class

5.2.2.3. Mexico

5.2.2.3.1. Mexico aneurysmal subarachnoid hemorrhage market, by drug class

5.2.3. North America market size and forecast by drug class

5.3. Europe

5.3.1. Key market trends, growth factors & opportunities
5.3.2. Market size and forecast by country

5.3.2.1. Germany

5.3.2.1.1. Germany aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.2. France

5.3.2.2.1. France aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.3. UK

5.3.2.3.1. UK aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.4. Italy

5.3.2.4.1. Italy aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.5. Spain

5.3.2.5.1. Spain aneurysmal subarachnoid hemorrhage market, by drug class

5.3.2.6. Rest of Europe

5.3.2.6.1. Rest of Europe aneurysmal subarachnoid hemorrhage market, by drug class

5.3.3. Europe market size and forecast by drug class

5.4. Asia-Pacific

5.4.1. Key market trends, growth factors & opportunities
5.4.2. Market size and forecast by country

5.4.2.1. Japan

5.4.2.1.1. Japan aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.2. China

5.4.2.2.1. China aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.3. Australia

5.4.2.3.1. Australia aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.4. India

5.4.2.4.1. India aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.5. South Korea

5.4.2.5.1. South Korea aneurysmal subarachnoid hemorrhage market, by drug class

5.4.2.6. Rest of Asia-Pacific

5.4.2.6.1. Rest of Asia-Pacific aneurysmal subarachnoid hemorrhage market, by drug class

5.4.3. Asia-Pacific market size and forecast by drug class

5.5. LAMEA

5.5.1. Key market trends, growth factors & opportunities
5.5.2. Market size and forecast by country

5.5.2.1. Brazil

5.5.2.1.1. Brazil aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.2. Saudi Arabia

5.5.2.2.1. Saudi Arabia aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.3. South Africa

5.5.2.3.1. South Africa aneurysmal subarachnoid hemorrhage market, by drug class

5.5.2.4. Rest of LAMEA

5.5.2.4.1. Rest of LAMEA aneurysmal subarachnoid hemorrhage market, by drug class

5.5.3. LAMEA market size and forecast by drug class

CHAPTER 6: COMPANY PROFILE

6.1. Arbor Pharmaceuticals Inc.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Key strategic moves and developments

6.2. Edge Therapeutics, Inc.

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Product portfolio
6.2.4. Business performance

6.3. Johnson & Johnson (Actelion Pharmaceuticals Ltd.)

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance

6.4. Mylan N.V.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance

6.5. Orexo AB

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Product portfolio
6.5.4. Business performance
6.5.5. Key strategic moves and developments

6.6. Pfizer Inc.

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance

6.7. Purdue Pharma L.P.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Product portfolio
6.7.4. Key strategic moves and developments

6.8. Pharmaxis, Ltd.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance

6.9. Sun Pharmaceutical Industries Ltd.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance

6.10. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Business performance